Novartis | NOVN - Current Assets


Novartis reported $27.35B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Alcon AG USD 6.62B 171M Mar/2026
Almirall EUR 747.1M 33.12M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Autolus Therapeutics Ltd USD 368.84M 67.08M Mar/2026
Bayer EUR 35.3B 2.39B Mar/2026
Biogen USD 7.31B 1.88B Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Fresenius EUR 12.07B 1.04B Mar/2026
Fresenius Medical Care EUR 8.11B 209.55M Mar/2026
Genmab DKK 2.88B 1.59B Dec/2025
Gilead Sciences USD 12.53B 6.11B Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
GRIFOLS EUR 5.31B 51M Jun/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
J&J USD 59.77B 601M Jun/2026
Lakefront Biotherapeutics EUR 3.06B 18.72M Mar/2026
Lonza CHF 8B 3.41B Dec/2025
Merck EUR 14.16B 932M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Novartis USD 27.35B 744M Jun/2026
Novartis USD 26.61B 3.85B Mar/2026
Novo Nordisk DKK 208.7B 31.38B Jun/2026
Orion EUR 1.2B 211.8M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Philips EUR 9.33B 454M Jun/2026
Recordati EUR 1.76B 29.78M Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
UCB EUR 6.05B 733M Dec/2025